Anti-cytokine therapy and plasma DNA in patients with rheumatoid arthritis

Lauková, Lucia; Konečná, Barbora; Vlková, Barbora; Mlynáriková, Vanda; Celec, Peter; Šteňová, Emőke

doi:10.1007/s00296-018-4055-8

Cited by 20 publications

(20 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These observations were in contrast to Hashimoto et al (163), where an increase in plasma cfDNA was observed until 8 weeks post-bDMARD treatment. However, in the absence of additional time points between baseline and 3 months, it is not possible to rule out the dynamics of cfDNA levels in the Laukova et al (164), study as well. Laukova et al (164) further observed that in RA patients, lower concentration of total cfDNA, correlated positively with DAS28, ESR and CRP.…”

Section: Cfdna and Treatment Response In Ramentioning

confidence: 97%

“…However, in the absence of additional time points between baseline and 3 months, it is not possible to rule out the dynamics of cfDNA levels in the Laukova et al (164), study as well. Laukova et al (164) further observed that in RA patients, lower concentration of total cfDNA, correlated positively with DAS28, ESR and CRP. No differences were found between good responders and moderate responders in the levels of total cfDNA, nuclear and mitochondrial cfDNA pre- and post-bDMARDs treatment.…”

Section: Cfdna and Treatment Response In Ramentioning

confidence: 97%

“…After the introduction of DMARDs, the cfDNA increase at 8 weeks was associated with a concomitant improvement in average SDAI score and disease activity. A study by Laukova et al (164), further investigated the effect of bDMARDs on plasma cfDNA with regards to it subcellular origin, nuclear, and mitochondrial, respectively. This study, in contrast to Hashimoto et al (163) demonstrated that plasma cfDNA decreases following dDMARDs therapy.…”

Section: Cfdna and Treatment Response In Ramentioning

confidence: 99%

“…Contrasting dynamics of cfDNA was observed with treatment for SLE and RA with cfDNA levels decreasing in SLE patients upon treatment (158, 160). In RA, however, cfDNA levels initially increase, where after they decrease at later time-points (163, 164). Finally, cfDNA levels associate with markers of disease activity and inflammation in both RA and SLE (2, 4, 42, 148–151, 153, 156–158, 161).…”

Section: Comparison Of Cfdna Observations Between Sle and Ramentioning

confidence: 99%

See 3 more Smart Citations

Cell-Free DNA as a Biomarker in Autoimmune Rheumatic Diseases

2019

View full text Add to dashboard Cite

Endogenous DNA is primarily found intracellularly in nuclei and mitochondria. However, extracellular, cell-free (cf) DNA, has been observed in several pathological conditions, including autoimmune diseases, prompting the interest of developing cfDNA as a potential biomarker. There is an upsurge in studies considering cfDNA to stratify patients, monitor the treatment response and predict disease progression, thus evaluating the prognostic potential of cfDNA for autoimmune diseases. Since the discovery of elevated cfDNA levels in lupus patients in the 1960s, cfDNA research in autoimmune diseases has mainly focused on the overall quantification of cfDNA and the association with disease activity. However, with recent technological advancements, including genomic and methylomic sequencing, qualitative changes in cfDNA are being explored in autoimmune diseases, similar to the ones used in molecular profiling of cfDNA in cancer patients. Further, the intracellular origin, e.g., if derived from mitochondrial or nuclear source, as well as the complexing with carrier molecules, including LL-37 and HMGB1, has emerged as important factors to consider when analyzing the quality and inflammatory potential of cfDNA. The clinical relevance of cfDNA in autoimmune rheumatic diseases is strengthened by mechanistic insights into the biological processes that result in an enhanced release of DNA into the circulation during autoimmune and inflammatory conditions. Prior work have established an important role of accelerated apoptosis and impaired clearance in leakage of nucleic acids into the extracellular environment. Findings from more recent studies, including our own investigations, have demonstrated that NETosis, a neutrophil cell death process, can result in a selective extrusion of inflammatory mitochondrial DNA; a process which is enhanced in patients with lupus and rheumatoid arthritis. In this review, we will summarize the evolution of cfDNA, both nuclear and mitochondrial DNA, as biomarkers for autoimmune rheumatic diseases and discuss limitations, challenges and implications to establish cfDNA as a biomarker for clinical use. This review will also highlight recent advancements in mechanistic studies demonstrating mitochondrial DNA as a central component of cfDNA in autoimmune rheumatic diseases.

show abstract

Section: Cfdna and Treatment Response In Ramentioning

confidence: 97%

Section: Cfdna and Treatment Response In Ramentioning

confidence: 97%

Section: Cfdna and Treatment Response In Ramentioning

confidence: 99%

Section: Comparison Of Cfdna Observations Between Sle and Ramentioning

confidence: 99%

See 2 more Smart Citations

Cell-Free DNA as a Biomarker in Autoimmune Rheumatic Diseases

2019

View full text Add to dashboard Cite

show abstract

“…This work described an increase in cfDNA 8 weeks after introducing bDMARDs associated with an improvement in disease activity. However, in a subsequent study, Lauková et al showed that plasma cfDNA decreases during dDMARD therapy [75], for which no clear conclusions can be drawn. Moreover, there is an important challenge in the selection of antitumour necrosis factor (TNF) drugs, where individual patients show great variability in response [76].…”

Section: Clinical Implication Of Cfdna In Autoimmune Rheumatic Diseasesmentioning

confidence: 97%

Circulating Free DNA and Its Emerging Role in Autoimmune Diseases

Mondelo‐Macía

Castro‐Santos

Castillo‐García³

et al. 2021

JPM

View full text Add to dashboard Cite

Liquid biopsies can be used to analyse tissue-derived information, including cell-free DNA (cfDNA), circulating rare cells, and circulating extracellular vesicles in the blood or other bodily fluids, representing a new way to guide therapeutic decisions in cancer. Among the new challenges of liquid biopsy, we found clinical application in nontumour pathologies, including autoimmune diseases. Since the discovery of the presence of high levels of cfDNA in patients with systemic lupus erythaematosus (SLE) in the 1960s, cfDNA research in autoimmune diseases has mainly focused on the overall quantification of cfDNA and its association with disease activity. However, with technological advancements and the increasing understanding of the role of DNA sensing receptors in inflammation and autoimmunity, interest in cfDNA and autoimmune diseases has not expanded until recently. In this review, we provide an overview of the basic biology of cfDNA in the context of autoimmune diseases as a biomarker of disease activity, progression, and prediction of the treatment response. We discuss and integrate available information about these important aspects.

show abstract